Avalere Vaccines: 2020 Mid-Year Outlook

Summary

Vaccine development is at the forefront of global efforts to address the COVID-19 pandemic, with a rapidly growing pipeline of candidates that will expand the existing vaccine landscape.

Please note: This is an archived post. Some of the information and data discussed in this article may be out of date. It is preserved here for historical reference but should not be used as the basis for business decisions. Please see our main Insights section for more recent posts.

Over the last decade, the landscape has evolved to encompass a growing adult immunization platform, yet a recent Avalere Health study found that Medicare spent $106 billion on vaccine-preventable disease costs from 2016 to 2018.

Despite pipeline advancements, access barriers across the lifespan remain, including fragmented coverage of vaccines and increasingly complex Advisory Committee on Immunization Practices recommendations. As novel vaccine candidates and delivery technologies advance—as well as candidates for previously nonvaccine preventable diseases—addressing these barriers will pave the way for better health outcomes.

Avalere’s dedicated team of policy, market access, and evidence professionals supports access strategies for innovative vaccines, and we are pleased to share our outlook of the vaccines marketplace in this publication.

Download the 2020 Mid-Year Outlook on Vaccines.

Check out our COVID-19 Intel Center.

To receive Avalere updates, connect with us.